Itepekimab (SAR440340)

Phase 3

Sanofi (SNYNF)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Oct '26

SNYPhase 3$100.0B

Itepekimab (SAR440340) Phase 3 Est. Readout

Itepekimab (SAR440340)• Chronic Rhinosinusitis With Nasal Polyps231

Oct 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Chronic Rhinosinusitis With Nasal Polyps

View Full Landscape

Drug Information

Target Indication

Chronic Rhinosinusitis With Nasal Polyps

Clinical Trial

NCT06834347

Last updated: 3/7/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

SNYNF

Sanofi

Biotechnology•North America•NASDAQ

Related Pipeline

IrbesartanPhase 3

Atrial Fibrillation

Teriflunomide (HMR1726)Phase 3

Multiple Sclerosis

DTaP-IPV-HB-PRP~T vaccinePhase 3

Diphtheria

Insulin glargine/lixisenatide Fixed Ratio CombinationPhase 3

Type 2 Diabetes

teriflunomide HMR1726Phase 3

Multiple Sclerosis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts